Sodium‐glucose co‐transporter‐2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials-Reference-Cited by-同舟云学术

Sodium‐glucose co‐transporter‐2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials

Published:2020-05-21 Issue:9 Volume:22 Page:1619-1627
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Liu Jiali¹^ORCID,Li Ling¹,Li Sheyu²,Wang Yuning¹,Qin Xuan¹,Deng Ke¹,Liu Yanmei¹,Zou Kang¹,Sun Xin¹³

Affiliation:

1. Chinese Evidence‐based Medicine Center, Cochrane China Center and National Clinical Research Center for Geriatrics, West China HospitalSichuan University Chengdu China

2. Department of Endocrinology and Metabolism, West China HospitalSichuan University Chengdu China

3. Evidence‐Based Medicine Research Center, School of Basic ScienceJiangxi University of Traditional Chinese Medicine Nanchang China

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14075

Reference34 articles.

1. Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update

2. Diabetic ketoacidosis: clinical characteristics, precipitating factors and outcomes of care;Barski L;Isr Med Assoc J.,2012

3. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. 2015.https://www.fda.gov/media/92185/download. Accessed May 12 2020.

4. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections.https://www.fda.gov/drugs/drug‐safety‐and‐availability/fda‐drug‐safety‐communication‐fda‐revises‐labels‐sglt2‐inhibitors‐diabetes‐include‐warnings‐about. Accessed January 20 2020.

5. Effect of Sodium–Glucose Cotransporter 2 Inhibitors on Diabetic Ketoacidosis Among Patients With Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials

Cited by 112 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Newer Outpatient Diabetes Therapies and Technologies;Medical Clinics of North America;2024-09

2. Effect of probiotics at different intervention time on glycemic control in patients with type 2 diabetes mellitus: a systematic review and meta-analysis;Frontiers in Endocrinology;2024-07-24

3. SGLT-2 inhibitors in heart failure and chronic kidney disease: A review for internists;Cleveland Clinic Journal of Medicine;2024-07

4. Cetoacidosis diabética;Acta Colombiana de Cuidado Intensivo;2024-07

5. Pathogenesis of euglycemic ketoacidosis associated with SGLT2 inhibitors;Anesteziologie a intenzivní medicína;2024-06-24